Why Is Arcutis Biotherapeutics Stock Surging Thursday?
Cantor Fitzgerald initiated Arcutis (ARQT) at Overweight with a $48 target, citing Zoryve's potential for $3.5B in peak sales.
Share
Why It Matters
A big investment bank believes Arcutis's skin medicine could become very popular and profitable. When smart money gets excited about a company's future, people notice and want to own it.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.